Compositions and methods for treatment
By identifying the interaction between 14-3-3θ protein and TDP-43 and developing targeted peptides, the treatment difficulties of ALS and FTD are solved, the clearance of pathological TDP-43 is achieved, related symptoms are improved, and new treatments are provided Ideas.
Patent Information
- Application Number
- CN202080071299.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-06-01
- Filing Date
- 2020-08-12
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2040-08-12
AI Technical Summary
Currently, effective treatments are lacking to deal with two neurodegenerative diseases related to TDP-43 pathology, rapid progressive and fatal amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), and existing studies have not yet been completed. Understand the pathological mechanisms of these diseases, especially the molecular mechanisms of TDP-43's cytoplasmic accumulation in diseases.
The inventors identified the 14-3-3θ protein as an interactive partner that promotes abnormal cytoplasmic localization of TDP-43 and developed specific peptides derived from 14-3-3θ, capable of targeting and removing pathological TDP-43, thereby Reversal of functional deficiencies associated with ALS and FTD. The method includes regulating the localization and expression of TDP-43 by targeting degradation domains and chimeric molecular techniques using a peptide containing a specific amino acid sequence or a nucleic acid molecule encoded therein.
By targeted degradation of pathological TDP-43, significantly improved ALS and FTD-related symptoms, including depression, motor deficits and decreased muscle strength, demonstrating potential new avenues for the treatment and prevention of these diseases.
Smart Images

Figure HDA0003589729520000011 
Figure HDA0003589729520000012 
Figure HDA0003589729520000021
Abstract
Description
Technical Field
[0001] The present disclosure relates to compositions and methods for treating and preventing neurodegenerative diseases characterized by or associated with TDP-43 pathology. The present disclosure also relates to isolated peptides and chimeric molecules suitable for treating and preventing said neurodegenerative diseases, as well as nucleic acids and gene constructs encoding said peptides and chimeric molecules. Background Art
[0002] Amyotrophic lateral sclerosis (ALS) is a motor neuron disease that affects motor neurons in both the brain and spinal cord. ALS is a fatal disease characterized by the loss of pyramidal cells in the motor cortex of the brain, premotor neurons in the spinal cord, and motor neurons in the brainstem, leading to muscle weakness and atrophy. ALS usually deteriorates rapidly after onset and usually leads to death within a few years.
[0003] Frontotemporal dementia (FTD) is characterized by progressive damage to the frontal and / or temporal lobes of the brain and is associated with progressive deterioration in decision-making ability, behavior, and language control. FTD is one of the most common forms of Alzheimer's disease, with a median life expectancy of less than 15 years after diagnosis.
[0004] ALS and FTD are both rapidly progressive and fatal neurodegenerative diseases with significant clinical, genetic and pathological overlaps. ALS and FTD are usually divided into familial (about 10% of cases, involving one or more clear gene mutations) or sporadic (about 90% of cases, where etiology is usually not well understood). The familial and sporadic forms of these diseases are clinically difficult to distinguish. The neuropathological feature of ALS and FTD is the deposition of TDP-43 in neurons. Current studies have shown that mislocalization of nuclear TDP-43 to the cytoplasm can trigger toxic events, including abnormal phosphorylation and fragmentation of TDP-43 (Shenouda et al., 2018, Adv Neurobiol 20: 239-263). However, the molecular mechanisms that regulate the physiological nuclear-cytoplasmic shuttling of TDP-43 during mRNA processing and drive cytoplasmic accumulation in disease remain unknown.
[0005] There is no cure for ALS or FTD. The prognosis is poor and treatments are limited. There is a clear need to develop new approaches to treat these debilitating diseases. Summary of the invention
[0006] The present disclosure is based on the inventors' identification of 14-3-3θ as a novel interacting partner of TDP-43 that promotes abnormal cytoplasmic localization of TDP-43 and contributes to the pathogenesis of ALS and FTD. The inventors have found that the use of specific peptides derived from 14-3-3θ can target and eliminate pathological TDP-43, thereby reversing the functional defects associated with ALS and FTD.
[0007] A first aspect of the present disclosure provides a method for treating or preventing a neurodegenerative disease associated with TDP-43 pathology or ameliorating at least one symptom thereof, the method comprising administering to a subject in need thereof an effective amount of a peptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or a conservative variant thereof, or a nucleic acid molecule encoding the peptide.
[0008] In a specific embodiment, the neurodegenerative disease is selected from amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). ALS can be familial ALS or sporadic ALS. FTD can be familial FTD or sporadic FTD. At least one symptom can include, for example, disinhibition, hyperactivity, movement deficits, or decreased muscle strength.
[0009] The amino acid sequence of SEQ ID NO: 1 may be provided within a larger contiguous peptide or polypeptide sequence. In an exemplary embodiment, the peptide sequence may comprise or consist of the amino acid sequence of SEQ ID NO: 2, a conservative variant thereof, or a sequence having at least about 75% identity to the sequence of SEQ ID NO: 2.
[0010] The nucleic acid molecule encoding the peptide of SEQ ID NO: 1 or a conservative variant thereof may comprise the nucleotide sequence of SEQ ID NO: 4 or a nucleotide sequence having at least about 70% identity to the sequence of SEQ ID NO: 4.
[0011] A nucleic acid molecule encoding the peptide of SEQ ID NO:2, a conservative variant thereof, or a sequence at least about 75% identical thereto may comprise the nucleotide sequence of SEQ ID NO:5, or a nucleotide sequence at least about 70% identical thereto.
[0012] In a specific embodiment, the peptide comprises or is linked to a protein destabilizing domain sequence. In an exemplary embodiment, the protein destabilizing domain sequence comprises rapamycin binding protein FKBP12.
[0013] Thus, in one embodiment, the method comprises administering to the subject a gene construct encoding a peptide comprising or consisting of a sequence of SEQ ID NO: 1 or a conservative variant thereof, the peptide being operably linked to a nucleotide sequence encoding a protein destabilizing domain.
[0014] A second aspect of the present disclosure provides use of a peptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or a conservative variant thereof, or a nucleic acid molecule encoding the peptide, in the manufacture of a medicament for treating or preventing a neurodegenerative disease associated with TDP-43 pathology or ameliorating at least one symptom thereof.
[0015] A third aspect of the present disclosure provides an isolated peptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or a conservative variant thereof.
[0016] The peptide may comprise or consist of the amino acid sequence of SEQ ID NO: 2, a conservative variant thereof, or a sequence having at least about 75% identity to the sequence of SEQ ID NO: 2.
[0017] A fourth aspect of the present disclosure provides an isolated polynucleotide encoding the peptide of the third aspect.
[0018] The polynucleotide may comprise or consist of the sequence of SEQ ID NO:4 or SEQ ID NO:5, or a polynucleotide having at least about 70% identity to the sequence of SEQ ID NO:4 or SEQ ID NO:5.
[0019] In exemplary embodiments of the third and fourth aspects, the peptide or polynucleotide is for use in treating or preventing a neurodegenerative disease associated with TDP-43 pathology or ameliorating at least one symptom thereof.
[0020] A fifth aspect of the present disclosure provides a chimeric molecule comprising a peptide comprising or consisting of an amino acid sequence of SEQ ID NO: 1 or a conservative variant thereof linked to a protein destabilizing domain sequence.
[0021] A sixth aspect of the present disclosure provides an isolated polynucleotide encoding the chimeric molecule of the fifth aspect.
[0022] In exemplary embodiments of the fifth and sixth aspects, the chimeric molecule or polynucleotide is for use in treating or preventing a neurodegenerative disease associated with TDP-43 pathology or ameliorating at least one symptom thereof.
[0023] A seventh aspect of the present disclosure provides a vector comprising the polynucleotide sequence of the fourth or sixth aspect.
[0024] The vector can be a viral vector. The viral vector can be an AAV vector. Typically, the vector is used to administer to a subject to treat or prevent a neurodegenerative disease associated with TDP-43 pathology or to improve at least one symptom thereof.
[0025] The vector can be designed for introduction into neurons or brain cells and direct or promote the expression of the encoded peptide or chimeric molecule in neurons or brain cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Aspects and embodiments of the present disclosure are herein described, by way of non-limiting example only, with reference to the following drawings.
[0027] Figure 1 .14-3-3θ interacts with TDP-43. Immunoprecipitation (IP) of 14-3-3θ / TDP-43 complexes from N2a cells (A) and mouse brain (B). Control (ctr) IP confirms the absence of nonspecific binding.
[0028] Figure 2 Co-expression showed that 14-3-3θ immunoprecipitation (IP) of TDP-43 with pathogenic mutations was significantly enhanced compared with its non-mutated form (n=3). ***P<0.001; **P<0.01; *P<0.05. Error bars represent SEM.
[0029] Figure 3 .(A) A315T mutant TDP-43, when expressed alone, localizes to the nucleus (+MOCK; arrows), but when expressed with 14-3-3θ, A315T-TDP-43 colocalizes to the cytoplasm (open arrows). (B) Coexpression shows that TDP-43 lacking (Δ) NLS or NES significantly enhances IP with 14-3-3θ compared to its non-mutant form (n=3). ****P<0.0001; *P<0.05. Error bars represent SEM. (C) Coexpression of 14-3-3θ confers cytoplasmic localization of ΔNES TDP-43 (open arrows), which is normally localized to the nucleus (solid arrows). As a comparison, the cytoplasmic localization of ΔNLS TDP-43 and the nuclear localization of non-mutant TDP-43 were not altered by 14-3-3θ.
[0030] Figure 4 N- and C-terminally truncated variants of 14-3-3θ immunoprecipitate with TDP-43 unless α-helix 6 is removed (ΔF). Note the enhanced 14-3-3θ / TDP-43 immunoprecipitation in the absence of α-helices 7-9 (ΔG).
[0031] Figure 5 Similar to the GΔ variant of 14-3-3θ, co-expression of 14-3-3θ α-helix 6 alone (14-3-3θ-Fx-V5) was immunoprecipitated with TDP-43.
[0032] Figure 6 Alignment of α-helix 6 of the 14-3-3 isoform corresponding to 14-3-3θ-Fx. Red box, sequence of 11 amino acids unique to 14-3-3θ.
[0033] Figure 7 (A) AAV-mediated expression of 14-3-3θ-V5 in the hippocampus resulted in the expression of control (ctr) and iTDP-43 A315TInsolubility and fragmentation of TDP-43 in mice (arrows). Quantification of TDP-43 fragment levels from independent experiments (n=6). ***P<0.001; *P<0.05. Error bars represent SEM. (B) iTDP-43 injected with AAV-vec (vector) and AAV-14-3-3θ-V5 A315T Quantification of hTDP-43-expressing neurons in the CA1 region of the hippocampus of mice. **P<0.01. Error bars represent SEM.
[0034] Figure 8 (A) Amino acids 135-164 of 14-3-3θ with a C-terminal degradation domain (DD) and an N-terminal V5 tag (DD-θFx) spontaneously degrade when expressed in primary neurons unless stabilized by treatment with Shield1. (B) DD-θFx reduces the level of co-expressed A315T mutant human (h) TDP-43 in primary neurons (n=4). Figure: left column, TDP-43; right column, TDP-43+DD-θFx. **, P<0.01. Error bars represent SEM.
[0035] Fig. 9 .(A) vec-injected iTDP-43 A315T The predominant nuclear hTDP-43 in the mouse cortex is significantly reduced in neurons expressing DD-θFx. (B) iTDP-43 expressing DD-θFx from birth A315T TDP-43 levels in the brain were reduced (n=3). mCherry and V5 confirmed AAV-mediated expression. Note that DD-θFx was expressed in iTDP-43 A315T The expression of iTDP-43 in vec mice was higher than that in control mice. Figure: Left column, P0: iTDP-43+vec; right column, P0: iTDP-43+DD-θFx. *, P<0.05. Error bars represent SEM.
[0036] Fig.10 (A) iTDP-43 treated with vec A315T Disinhibition of mice (as reflected by increased open arm activity time in the elevated plus maze) was significantly reduced upon DD-θFx expression (n=8). (B) iTDP-43 treated with vec A315T The increased activity of mice (as reflected by longer distances traveled in an open field) was significantly reduced upon DD-θFx expression (n=8). (C) iTDP-43 treated with vec A315T The reduced motor ability of mice (as reflected by the shorter time to fall off the rotating rod) upon DD-θFx expression was comparable to that of ctr mice (n=8). (D) iTDP-43 treated with vec A315TThe reduced grip strength of mice was significantly greater upon DD-θFx expression (n=8). For (A)–(D): first column, P0: ctr+vec; second column, P0: ctr+DD-θFx; third column, P0: iTDP-43+vec; fourth column, P0: iTDP-43+DD-θFx. vec=vehicle. ctr=control. ***P<0.001; **P<0.01; *P<0.05; ns, not significant. Error bars represent SEM.
[0037] Fig.11 (A) iTDP-43 expressing DD-θFx-V5 compared with mCherry A315T Reduced levels of transgenic hTDP-43 in mice (n=3). Figure: Left column, iv: iTDP-43+vec; Right column, iv: iTDP-43+DD-θFx. vec=vector. *P<0.05. Error bars represent SEM. (B) Brain staining of vec-expressing and DD-θFx-expressing mice shows a reduction in the number of hTDP-43-positive cells in the hippocampus (n=6). Figure: Left column, iv: iTDP-43+vec; Right column, iv: iTDP-43+DD-θFx. vec=vector. **P<0.01. Error bars represent SEM.
[0038] Fig.12 .vec processed iTDP-43 A315T Disinhibition of mice was significantly improved upon DD-θFx expression (n=6). First column, iv: ctr+vec; second column, iv: ctr+DD-θFx; third column, iv: iTDP-43+vec; fourth column, iv: iTDP-43+DD-θFx. vec=vehicle. ctr=control. ***P<0.001; **P<0.01; *P<0.05. Error bars represent SEM.
[0039] Fig.13 .Progressive decline in physical strength in vec-treated AAV-hTDP-43 mice as reflected by reduced inverted wire time (A) and corresponding linear regression slope differences (B) comparable to AAV-DD-θFx-injected AAV-hTDP mice and controls (n=10). B: First column, AAV-vec+AAV-vec; second column, AAV-vec+AAV-DD-θFx; third column, AAV-hTDP-43+AAV-vec; fourth column, AAV-hTDP-43+AAV-DD-θFx. *P<0.05, ***P<0.001. Error bars represent SEM.
[0040] Fig.14 . Grip strength was reduced in AAV-vec treated AAV-hTDP-43 mice compared to AAV-DD-θFx injected AAV-hTDP-43 mice (n=7). First column, AAV-hTDP-43+AAV-vec female mice; second column, AAV-hTDP-43+AAV-DD-θFx female mice; third column, AAV-hTDP-43+AAV-vec male mice; fourth column, AAV-hTDP-43+AAV-DD-θFx male mice. *P<0.05. Error bars represent SEM.
[0041] Fig.15 Tibialis anterior (TA) muscle atrophy as indicated by weight loss in female and male vec-treated AAV-hTDP-43 mice, comparable to AAV-DD-θFx-injected AAV-hTDP mice (n=3-7). For female and male mice: first column, AAV-vec+AAV-vec; second column, AAV-vec+AAV-DD-θFx; third column, AAV-hTDP-43+AAV-vec; fourth column, AAV-hTDP-43+AAV-DD-θFx. *P<0.05, ***P<0.001. Error bars represent SEM.
[0042] Amino acid and nucleotide sequences are referred to by sequence identifiers (SEQ ID NOs). The sequences are provided in the sequence table. The amino acid sequence shown in SEQ ID NO: 1 represents an 11 amino acid motif of α helix 6 (αF) from human 14-3-3θ, and the DNA sequence encoding the motif is shown in SEQ ID NO: 4. The amino acid sequence shown in SEQ ID NO: 2 represents a 30 amino acid region of αF from human 14-3-3θ, and the DNA sequence encoding the region is shown in SEQ ID NO: 5. The amino acid sequence of human 14-3-3θ is shown in SEQ ID NO: 3. Other nucleotide sequences used in the studies described in the examples, including primer sequences, are shown in SEQ ID NOs: 6 to 20. DETAILED DESCRIPTION
[0043] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which the present disclosure belongs. Unless otherwise stated, all patents, patent applications, published applications and publications, databases, websites and other published materials mentioned throughout the disclosure are incorporated by reference as a whole. In the case where there are multiple definitions of terms, those in this section shall prevail. In the case of referring to URLs or other such identifiers or addresses, it should be understood that such identifiers may change, and specific information on the Internet may come and go, but equivalent information can be found by searching the Internet. Reference to identifiers proves the availability and public dissemination of such information.
[0044] As used herein, a noun not limited by a quantifier refers to one or more than one (ie, at least one) of the referent. For example, "an element" refers to one element or more than one element.
[0045] In the context of this specification, the term "about" is understood to refer to a range of numbers that one skilled in the art considers equivalent to the recited values in the context of achieving the same function or result.
[0046] Throughout this specification and the appended claims, unless the context requires otherwise, the word "comprise" and variations such as "comprising" or "containing", will be understood to imply the inclusion of stated integers or steps or groups of integers or steps but not the exclusion of any other integers or steps or groups of integers or steps.
[0047] As used herein, the term "operably linked" refers to a functional connection between two elements, regardless of the orientation or distance between the two elements, such that the function of one element is controlled or affected by the other element. For example, an operable connection with respect to a promoter and a nucleic acid sequence refers to transcription and expression of the nucleic acid sequence being under the control of the promoter or driven by the promoter. In another example of the present disclosure, an operable connection between two nucleotide sequences can result in a physical connection or coupling between the expressed encoded peptides or polypeptides, thereby forming a chimeric molecule.
[0048] The term "optionally" is used herein to indicate that a subsequently described feature may or may not exist, or a subsequently described event or circumstance may or may not occur. Thus, this specification will be understood to include and encompass embodiments in which the feature exists and embodiments in which the feature does not exist, and embodiments in which the event or circumstance occurs and embodiments in which the event or circumstance does not occur.
[0049] The term "peptide" refers to a polymer consisting of amino acids linked together by peptide bonds. The term "polypeptide" may also be used to refer to such a polymer, although in some cases a polypeptide may be longer than a peptide (i.e., consisting of more amino acid residues). Nevertheless, the terms "peptide" and "polypeptide" are used interchangeably herein.
[0050] As used herein, the terms "treating," "treatment," "preventing," "prevention," and grammatical equivalents refer to any and all uses of remediating the described neurodegenerative disease, preventing, slowing or delaying the development of the disease, or otherwise preventing, hindering, delaying or reversing the progression of the disease. Therefore, the terms "treatment" and "prevention," etc. should be considered in their broadest context. For example, treatment does not necessarily mean treating a patient until full recovery. In cases where a disease manifests or is characterized by multiple symptoms, treatment or prevention does not necessarily require remediation, prevention, hindering, delaying or reversing all of the described symptoms, but rather may prevent, hinder, delay or reverse one or more of the described symptoms.
[0051] As used herein, the term "effective amount" includes within its meaning an amount or dosage of an agent or compound that is nontoxic but sufficient to provide the desired effect. The exact amount or dosage required will vary from subject to subject, depending on factors such as the species being treated, the age, size, weight and general condition of the subject, the severity of the disease or condition being treated, the specific agent being administered, and the mode of administration, etc. Therefore, it is not possible to specify an exact "effective amount". However, for any given situation, a suitable "effective amount" can be determined by one of ordinary skill in the art using only routine experimentation.
[0052] As used herein, the term "subject" refers to a mammal, and includes humans, primates, livestock (e.g., sheep, pigs, cattle, horses, donkeys), laboratory test animals (e.g., mice, rabbits, rats, guinea pigs), performance and display animals (e.g., horses, livestock, dogs, cats), companion animals (e.g., dogs, cats), and captive wild animals. Preferably, the mammal is a human or a laboratory test animal. Even more preferably, the mammal is a human.
[0053] TDP-43 is a multifunctional RNA / DNA binding protein encoded by the TARDBP gene. It has two RNA recognition motifs and a large C-terminal glycine-rich domain (GRD) that mediates protein-protein interactions. The G-rich domain contains the vast majority of pathogenic TARDBP mutations in familial ALS. However, before the present invention, little was known about the functional effects of TDP-43 interactions in physiology and disease.
[0054] As exemplified herein, the inventors have identified protein 14-3-3θ as a new interaction partner of TDP-43. Pathogenic variants of TDP-43 show increased interactions with 14-3-3θ, resulting in cytoplasmic accumulation, insolubility, phosphorylation and fragmentation of TDP-43, similar to the pathological changes of the disease. Without wishing to be bound by theory, the inventors propose that transient interactions with 14-3-3θ can stabilize TDP-43 while it resides in the cytoplasm during RNA shuttling. The inventors further propose that 14-3-3θ interacts with abnormal TDP-43 conformations and makes them susceptible to pathological modifications.
[0055] As exemplified herein, the inventors demonstrate the use of a unique peptide sequence derived from 14-3-3θ to mediate the removal of pathological TDP-43 from the mouse brain and to reverse and prevent ALS and FTD-related symptoms. Although exemplified herein in the context of this peptide sequence conjugated to a protein destabilizing domain, the present disclosure contemplates the use of the peptide in the absence of a protein destabilizing domain. Without wishing to be bound by theory, the inventors propose that the peptide interferes with the physiological and / or pathological interactions between 14-3-3θ and TDP-43, thereby preventing the toxic downstream effects of the 14-3-3θ / TDP-43 complex.
[0056] In one aspect, the present disclosure provides a method for treating or preventing a neurodegenerative disease associated with TDP-43 pathology or ameliorating at least one symptom thereof, the method comprising administering to a subject in need thereof a peptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or a conservative variant thereof, or a nucleic acid molecule encoding the peptide.
[0057] Embodiments of the present disclosure are suitable for treating or preventing any neurodegenerative disease characterized by or otherwise associated with TDP-43 pathology. Typically, such diseases are characterized by or associated with cytoplasmic accumulation of nuclear TDP-43 and abnormal phosphorylation and fragmentation of TDP-43. In specific embodiments, the disease is amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD). ALS can be familial or sporadic ALS. FTD can be familial or sporadic FTD.
[0058] Symptoms of neurodegenerative diseases include behavioral and physical defects that are characteristic of or associated with the disease. Therefore, according to the present disclosure, the administration of peptides or nucleic acid molecules encoding the peptides can improve one or more behavioral or physical defects that are characteristic of or associated with neurodegenerative diseases. Such behavioral and physical defects include disinhibition, hyperactivity, motor deficits, and decreased muscle strength.
[0059] Many pathogenic variants of TDP-43 are known to be associated with sporadic or familial ALS and FTD, including, for example, A315T, N345K, M337V, G294A, A382T and G287S mutations. However, those skilled in the art will recognize that the scope of the present disclosure is not limited to treating or preventing neurodegenerative diseases in individuals carrying one or more of these mutations.
[0060] The peptide RKQTIDNSQGA (SEQ ID NO: 1) for use in accordance with aspects and embodiments of the present disclosure is an 11 amino acid motif present within alpha helix 6 (αF) of human 14-3-3θ (corresponding to amino acid residues 138-148 of wild-type human 14-3-3θ as set forth in SEQ ID NO: 3).
[0061] Conservative variants of the peptide of SEQ ID NO: 1 are also contemplated herein. Conservative variants comprise one or more conservative amino acid substitutions, i.e., substitution or replacement of one amino acid with another amino acid having similar properties, as will be well understood by those skilled in the art. For example, substitution of a neutral amino acid serine (S) for a similar neutral amino acid threonine (T) would be a conservative amino acid substitution. Those skilled in the art will be able to determine suitable conservative amino acid substitutions that do not eliminate the functional properties of the peptide in terms of TDP-43 interaction.
[0062] Therefore, the present invention also provides an isolated peptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or a conservative variant thereof. In the present invention, the term "isolated" refers to as used herein, "isolated" with respect to nucleic acid molecules means that the peptide is substantially free of cellular material or other contaminating proteins from the cell from which the peptide is derived (thus altered from its native state), or substantially free of chemical precursors or other chemicals when chemically synthesized, thus altered from its native state.
[0063] The peptide of SEQ ID NO: 1 or its conservative variant can be provided within a larger continuous peptide or polypeptide sequence. The peptide sequence comprising the sequence of SEQ ID NO: 1 can comprise, for example, about 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 residues, typically as a continuous sequence. For example, the peptide of SEQ ID NO: 1 used in accordance with the present disclosure can be provided as a portion of the αF helix sequence of 14-3-3θ, such as a sequence comprising amino acids 135 to 164 (SEQ ID NO: 2) of human 14-3-3θ (SEQ ID NO: 3) or a portion thereof, or a sequence having at least about 75% identity thereto. For example, the length of the sequence of the αF helix comprising the sequence of SEQ ID NO: 1 can be 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more amino acids.
[0064] In one embodiment, the peptide may comprise or consist of an amino acid sequence of SEQ ID NO:2, a conservative variant thereof, or a sequence having at least about 75% identity to the sequence of SEQ ID NO:2. The sequence may have about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to the sequence of SEQ ID NO:2. Therefore, a separated peptide is also provided herein, comprising or consisting of an amino acid sequence of SEQ ID NO:2, a conservative variant thereof, or a sequence having at least about 75% identity to the sequence of SEQ ID NO:2.
[0065] The peptide comprising the sequence of SEQ ID NO:1 or its conservative variant or consisting thereof can include or be connected to one or more other parts to promote, for example, transport, cell recognition, targeting or other functions, such as protein destabilization or degradation. For example, the peptide can be connected to or include a cell targeting portion, which helps to target the peptide to one or more specific types, such as neurons or other cells of the central nervous system. For example, as further described below, the peptide can include or be connected to a protein destabilization or degradation signal or domain to destroy stability and / or induce degradation in vivo. The peptide can be connected to one or more other parts by any method known in the art (including any chemical or recombinant method), and when appropriate, covalent and / or non-covalent bonds are formed between the molecule and one or more other parts. These parts can be peptides, polypeptides or protein parts. Therefore, the present disclosure further provides chimeric peptides, polypeptides and proteins comprising the sequence RKQTIDNSQGA (SEQ ID NO:1) or its conservative variants conjugated to heterologous peptides, polypeptides or proteins. 400, 450, 500, 600, 700, 800, 900, 1000, 1500, or 2000 residues in length.
[0066] The peptide or conservative variant of SEQ ID NO: 1 can be conjugated to the C-terminus or N-terminus of the additional peptide, polypeptide or protein moiety. The component molecules can be conjugated using, for example, standard chemical coupling techniques such as MBS, glutaraldehyde, EDC or BDB coupling, or can be connected by peptide synthesis methods or recombinant methods known to those skilled in the art.
[0067] In a specific embodiment of the present disclosure, a peptide comprising a sequence of SEQ ID NO:1 or a conservative variant thereof is conjugated to or comprises a portion providing a protein destabilization or degradation signal. In an exemplary embodiment, a protein destabilization or degradation signal is provided by a protein destabilization or degradation domain (herein referred to as a "destabilization domain" for convenience). A "destabilization domain" refers to a protein, a polypeptide or an amino acid sequence, which, when functionally coupled to a peptide, a polypeptide or a protein of interest, can destroy the stability of the peptide, polypeptide or protein of interest and optionally induce degradation. Examples of destabilization domains well known to those skilled in the art include ubiquitin, PEST sequences (sequences rich in proline, glutamic acid, serine and threonine), cyclin destruction boxes, hydrophobic extension fragments of amino acids and rapamycin binding protein FKBP12 (e.g., found in pTuner plasmids, Clontech). Suitable destabilization domains can be introduced into the peptide sequence of the present disclosure, or conjugated to the N- or C-terminus of a peptide with or without a joint. For embodiments where it is desired to include a destabilizing domain, those skilled in the art will appreciate that any suitable destabilizing domain may be employed and that the scope of the present disclosure is not limited by reference to any particular destabilizing domain.
[0068] Also provided herein are chimeric peptides, polypeptides and proteins comprising a peptide of SEQ ID NO: 1 or a conservative variant thereof conjugated to a protein destabilizing domain sequence. Also provided herein are chimeric peptides, polypeptides and proteins comprising a peptide of SEQ ID NO: 2, a conservative variant thereof or a sequence having at least about 75% identity to the sequence of SEQ ID NO: 2 conjugated to a protein destabilizing domain sequence.
[0069] The peptides and polypeptides disclosed herein can be produced using any method known in the art, including chemical synthesis techniques, nucleic acid synthesis techniques, peptide synthesis techniques and / or recombinant techniques. In one example, a peptide such as the peptide of SEQ ID NO: 1 is synthesized using the Fmoc-polyamide mode of solid phase peptide synthesis. Other synthetic methods include solid phase t-Boc synthesis and liquid phase synthesis. Purification can be performed by any one or a combination of techniques, such as recrystallization, size exclusion chromatography, ion exchange chromatography, hydrophobic interaction chromatography, and reversed phase high performance liquid chromatography, using, for example, acetonitrile / water gradient separation.
[0070] Alternatively, recombinant methods well known in the art can be used to produce peptides and polypeptides. Nucleic acids encoding peptides and polypeptides can be obtained by any suitable method, such as synthesis of oligonucleotides encoding polypeptides of the present invention by RT-PCR or. Therefore, as further described below, nucleic acid molecules encoding peptides and polypeptides (including chimeric peptides and polypeptides disclosed herein) are also provided herein. Designing nucleic acid molecules encoding peptides and polypeptides (including chimeric peptides and polypeptides disclosed herein) is fully within the skill range of those skilled in the art.
[0071] The disclosure also contemplates and encompasses peptide mimetics of the peptide sequences disclosed herein. As used herein, the term "peptide mimetic" refers to a peptide-like molecule having the ability of a peptide based on the structure to interact with TDP-43. Such peptide mimics include chemically modified peptides, peptide-like molecules containing non-naturally occurring amino acids, and peptoids (see, e.g., Goodman and Ro, Peptidomimetics for Drug Design, in "Burger's Medicinal Chemistry and Drug Discovery" Vol. 1 (ed. ME Wolff; John Wiley & Sons 1995), pp. 803-861). A variety of peptide mimetics are known in the art, including, for example, peptide-like molecules containing restricted amino acids (e.g., α-methylated amino acids, α, α-dialkylglycine, α-, β- or γ-aminocycloalkanecarboxylic acids, α, β-unsaturated amino acids, β, β-dimethyl or β-methyl amino acids or other amino acid mimetics), non-peptide components that mimic peptide secondary structures (e.g., non-peptide 3-turn mimetics, γ-turn mimetics, β-sheet structure mimetics or helical structure mimetics), or amide bond isosteres (e.g., reduced amide bonds, methylene ether bonds, ethylene bonds, thioamide bonds or other amide isosteres). Methods for identifying peptide mimetics are also well known in the art and include, for example, screening databases containing libraries of potential peptide mimetics.
[0072] The present disclosure also provides isolated nucleic acid molecules encoding the peptides and chimeric peptides as described herein, and methods of administering the nucleic acid molecules (generally as part of a vector or similar genetic construct) to a subject in need thereof.
[0073] For example, a nucleic acid molecule encoding the peptide of SEQ ID NO: 1 or a conservative variant thereof can comprise the nucleotide sequence set forth in SEQ ID NO: 4, or a sequence having at least or about 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence set forth in SEQ ID NO: 4. For example, a nucleic acid molecule encoding a peptide of SEQ ID NO: 2, a conservative variant thereof, or a sequence having at least about 75% identity to the sequence of SEQ ID NO: 2 can include a nucleotide sequence as shown in SEQ ID NO: 5, or a sequence having at least or about 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence as shown in SEQ ID NO: 5. The nucleic acid molecule can also include a nucleotide sequence of a selected protein destabilizing domain operably linked to the above nucleotide sequence, thereby expressing a chimeric peptide or polypeptide.
[0074] The disclosure also provides a vector comprising one or more nucleotide sequences described herein. Typically, the nucleotide sequence is operably linked to a promoter to allow expression of a peptide or polypeptide. The vector may be an additional vector (i.e., not integrated into the host cell genome), or may be a vector integrated into the host cell genome. The vector may have replication capability or replication defects. Exemplary vectors include, but are not limited to, plasmids, cosmids, and viral vectors, such as adeno-associated virus (AAV) vectors, lentiviruses, retroviruses, adenoviruses, herpes viruses, parvoviruses, and hepatitis virus vectors. The selection and design of suitable vectors are within the capabilities and judgment of those of ordinary skill in the art.
[0075] Provided herein are polynucleotides comprising expression cassettes or expression constructs, which can be used to express peptides, polypeptides, or chimeric peptides or polypeptides as described herein in suitable vectors for gene therapy. Therefore, in a specific embodiment, the method of the present disclosure includes administering a vector to a subject in need, the vector comprising a nucleotide sequence encoding the peptides and polypeptides disclosed herein, usually operably linked to a heterologous promoter, so that the peptide, polypeptide, or chimeric peptide or polypeptide of interest is expressed in vivo. In a specific exemplary embodiment, the vector is a viral vector. As used herein, the term "viral vector" refers to a vector derived from any virus and generally includes at least one starting point element and has the ability to be packaged into a recombinant virus or virion. The viral vector may have all or part of one or more wild-type genes of the virus from which the vector is derived, but retains functional flanking ITR sequences, which are necessary for the rescue, replication, and packaging of the virion. Therefore, the viral vector generally comprises at least a cis sequence (e.g., functional ITR) required for viral replication and packaging. ITR does not have to be a wild-type nucleotide sequence, and can be changed, for example, by insertion, deletion, or substitution of nucleotides, as long as the sequence provides functional rescue, replication, and packaging. Vectors and / or virions can be used to transfer heterologous sequences into cells in vitro or in vivo.
[0076] In a specific embodiment, the vector is an AAV vector, i.e., a vector derived from an adeno-associated virus, including but not limited to AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12 or AAV13, or using a synthetic or modified AAV capsid protein, such as those optimized for efficient in vivo transduction (e.g., central nervous system). Recombinant AAV vectors describe replication-defective viruses that include an AAV capsid that encapsulates an AAV genome. Typically, one or more wild-type AAV genes have been deleted in whole or in part from the genome, preferably rep and / or cap genes. Functional ITR sequences are essential for rescuing, replicating and packaging the vector genome into rAAV virions.
[0077] AAV ITR can be derived from any of several AAV serotypes, including but not limited to AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, etc., or can be synthetic. The technician can make the selection without excessive experimentation. The length of AAV ITR is generally about 145 nucleotides, although it is not necessary to have a wild-type nucleotide sequence, that is, it can be changed by insertion, deletion and / or substitution of nucleotides, as long as they are functional. In addition, the ITRs in the polynucleotide do not have to be identical or derived from the same AAV serotype or isolate, as long as they function as expected, that is, help rescue, replicate and package transgenes. The nucleotide sequences of AAV ITR are well known in the art.
[0078] The vector used according to the present disclosure may also include a transcription enhancer, a translation signal, and a transcription and translation termination signal. Examples of transcription termination signals include, but are not limited to, polyadenylation signal sequences, such as bovine growth hormone (BGH) poly (A), SV40 late poly (A), rabbit β-globin (RBG) poly (A), thymidine kinase (TK) poly (A) sequence and any variants thereof. In some embodiments, the transcription termination region is located downstream of the post-transcriptional regulatory element. In some embodiments, the transcription termination region is a polyadenylation signal sequence.
[0079] The vector used according to the present disclosure may also include various post-transcriptional regulatory elements. In some embodiments, the post-transcriptional regulatory element may be a viral post-transcriptional regulatory element. Non-limiting examples of viral post-transcriptional regulatory elements include woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), hepatitis B virus post-transcriptional regulatory element (HBVPRE), RNA transport element and any variant thereof.
[0080] The disclosure contemplates that peptides, polypeptides, polynucleotides and carriers are delivered to a subject in need of treatment by any suitable means, and usually in the form of a pharmaceutical composition, which may include one or more pharmaceutically acceptable carriers, excipients or diluents. Such compositions may be administered by any convenient or suitable route, such as by parenteral (e.g., intraperitoneal, subcutaneous, intraarterial, intravenous, intramuscular), oral (including sublingual), nasal or topical routes. In the case where it is necessary to deliver molecules of appropriate concentrations directly to the site to be treated in vivo, administration may be regional rather than systemic. Regional administration provides the ability to deliver molecules of very high local concentrations to the desired site, and is therefore suitable for achieving desired therapeutic or preventive effects, while avoiding exposure of other organs of the body to carriers and molecules, thereby potentially reducing side effects.
[0081] It should be understood that the specific dosage level of the composition of the present invention for any particular subject will depend on a variety of factors, including, for example, the activity of the specific medicament used, the age, weight, general health and diet of the individual to be treated, the time of administration, the frequency of excretion and the combination with any other treatment or therapy. Single or multiple administrations can be performed, and the dosage level and mode are selected by the treating physician. A wide range of dosages can be applied. Considering the patient, for example, about 0.1 mg to about 1 mg of medicament can be administered per kilogram of body weight per day. The dosage regimen can be adjusted to provide the best therapeutic response. For example, several separate doses can be administered every day, every week, every month or at other suitable time intervals, or the dosage can be reduced proportionally according to the emergency of the situation.
[0082] Examples of pharmaceutically acceptable carriers or diluents are demineralized or distilled water; physiological saline; vegetable oils, such as peanut oil, safflower oil, olive oil, cottonseed oil, corn oil, sesame oil, arachis oil, oil) or coconut oil; silicone oils, including polysiloxanes, such as methylpolysiloxane, phenylpolysiloxane and methylphenylpolysiloxane; volatile silicones; mineral oils, such as liquid paraffin, soft paraffin or squalane; cellulose derivatives, such as methylcellulose, ethylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose or hydroxypropylmethylcellulose; lower alkanols, such as ethanol or isopropanol; lower aryl alkanols; lower polyalkylene glycols or lower alkylene glycols, such as polyethylene glycol, polypropylene glycol, ethylene glycol, propylene glycol, 1,3-butylene glycol or glycerol; fatty acid esters, such as isopropyl palmitate, isopropyl myristate or ethyl oleate; polyvinyl pyrrolidone; agar; carrageenan; tragacanth gum or gum arabic and vaseline. Typically, one or more carriers will form 10% to 99.9% by weight of the composition.
[0083] The present invention contemplates combination therapy in which peptides, polypeptides, polynucleotides and vectors as described herein are co-administered with other suitable agents that promote the desired therapeutic or preventive outcome. "Co-administration" refers to simultaneous administration by the same or different routes, or sequential administration by the same or different routes, in the same formulation or in two different formulations. "Sequential" administration refers to a time difference of seconds, minutes, hours or days between administration of the agents. Administration can be performed in any order.
[0084] Reference in this specification to any previous publication (or information derived therefrom) or any known matter is not and should not be taken as an acknowledgement or acknowledgment or any form of suggestion that the previous publication (or information derived therefrom) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.
[0085] The present disclosure will now be described with reference to the following specific examples, which should not be construed as limiting the scope of the present disclosure in any way.
[0086] Example
[0087] The following examples are illustrative of the present disclosure and should not be construed as limiting in any way the general nature of the disclosure described throughout the specification.
[0088] General approach
[0089] Bacterial two-hybrid screening. The BacterioMatch II two-hybrid system was performed according to the manufacturer's instructions (Chem-Agilent). In brief, the carboxyl terminal portion of human TDP-43 (amino acids 259-415 of the human TDP-43 sequence corresponding to UniProt accession number Q13148) was cloned into the pBT (bait) vector and used to identify interaction partners from the human brain cDNA pTRG plasmid library. Detection of protein-protein interaction partners is based on transcriptional activation of the HIS3 reporter gene, and positivity is further verified by a secondary streptomycin resistance reporter. All proliferation and transformation were completed using chemically competent cells provided in the kit. Colonies were visualized to obtain images by incubating the growth plates with 2% TTC / PBS (Sigma) at 37°C for 10 minutes.
[0090] Cloning. Point mutations and truncated variants were generated by standard site-directed mutagenesis (Ittner et al., 2005, Biochemistry 44: 5749-5754). 14-3-3θ MISSION shRNA lentivirus (Sigma-Aldich) with the sequence CCGGCAGTTGCTTAGAGACAACCTACTCGAGTAGGTTGTCTCTAAGCAACTGTTTTTG (SEQ ID NO: 6) was used to knock down 14-3-3θ. Stable overexpression of 14-3-3θ (C-terminal V5-tag) in SH-SY5Y cells was achieved using lentivirus (cloning vector pLenti6 / Ubc; Life Technologies). All 14-3-3 isoforms were cloned into pcDNA3.1 / myc (Life Technologies) with a C-terminal myc tag, and TDP-43 wild type / mutants were cloned into pcDNA3.1 / V5 (Life Technologies) with a C-terminal V5 tag for immunoprecipitation.
[0091] Adeno-associated virus. 14-3-3θ (with V5 tag) was cloned into rAAV vector under human synapsin promoter using plasmid pAAV-hSyn-EGFP (Addgene, #50465) as backbone and removing EGFP. The same vector or variant used for mCherry expression was used as control. The rAAV9 vector was packaged using capsid AAV9.PHP.B (Deverman et al., 2016, Nat Biotechnol 34:204-209) as previously described (Bi et al., 2017, Nat Commun 8:473). 2 μl rAAV (1×10 13 viral genomes / ml) were injected into 3-month-old wild-type or iTDP-43 A315T Mouse hippocampus (-1.94 mm AP, 1.6 mm ML, 1.8 mm DV from λ) (Ke et al., 2015, Acta Neuropathol 130:661-678). For spinal injection, 1 μl rAAV (1×10 13 Viral genomes / ml) were injected directly into the spinal cord of cryoanesthetized newborn pups (P0-2). All animal experiments were approved by the Macquarie University Animal Ethics Committee.
[0092] Immunoprecipitation. Immunoprecipitation was performed as previously described (Ittner et al., 2009, J Biol Chem 284: 20909-20916). In brief, 293T HEK cells were co-transfected with TDP-43 variants and / or 14-3-3 isoforms / variants in pcDNA3.1 / V5. Cells were lysed in RIPA buffer. Equal amounts of protein were incubated overnight with 1 μl V5 antibody (Life Technologies) and precipitated using magnetic protein G beads (Life Technologies). Immunoprecipitation was further confirmed by Western blotting using myc antibody.
[0093] Western blotting. Western blotting was performed as previously described (Ke et al., 2012, PLoS One 7:e35678). The primary antibodies used for immunoblotting were human TDP-43, c-terminal TDP-43, pan-TDP-43 (Proteintech), 14-3-3θ (Abcam), V5, myc (Life Technologies), phospho-TDP-43S409 / 410 (Cosmobio), GAPDH (Merck-Millipore).
[0094] Cell culture and staining. All immunoprecipitation experiments were performed in 293T HEK cells. According to standard protocols, cells were maintained in DMEM containing 10% fetal bovine serum (FBS). SH-SY5Y cells were maintained in DMEM / F-12 containing 10% FBS and used for 14-3-3θ overexpression or knockdown. Stable overexpression and knockdown of 14-3-3θ were achieved by lentiviral transduction. For immunocytochemistry, cells were fixed in 4% PFA and blocked with 3% heat-inactivated goat serum / 2% BSA. Antibodies V5 (Sigma), myc (Life Technologies) and secondary antibodies Alexa Fluor 488, 555 (Life Technologies) were used. Coverslips were fixed in Immun-Mount (Southern Biotech).
[0095] Microscopy. All fluorescence images of cell cultures were taken using a BX51 epifluorescence or confocal FV10i microscope (Olympus).
[0096] In vitro complex assay. HEK293T cells were transfected with full-length wild-type TDP-43 or TDP-43 or 14-3-3θ (with polyhistidine-tag) with F147L / F149L double mutations (both with c-terminal V5 tags). Cells transfected with TDP-43 constructs were lysed in immunoprecipitation buffer (IPB) (20mM Tris-HCl (pH 7.8), 150mM NaCl, 0.1% (v / v) NP-40) supplemented with a complete protease inhibitor cocktail (Roche) without EDTA, and TDP-43 with a V5 tag was IPed with a mouse anti-v5 antibody (Life Technologies) (as above). Subsequently, the lysate was washed twice with IPB, washed twice with DNase / RNase buffer (DRB) (10mM Tris-HCl (pH 7.6), 2.5mM MgCl2, and 0.5mM CaCl2), and reconstituted in DRB. 14-3-3θ-HIS transfected cells were lysed in IPB and purified by TALON resin (Clontech Laboratories). Briefly, the lysate was incubated with TALON resin at 4°C for 2 hours, washed three times with IPB and eluted in in vitro interaction buffer (IVIB) (20mM Tris-HCl (pH 7.8), 0.1M NaCl, 20% (v / v) glycerol, 5mM MgCl2, 5mM CaCl2, 0.1% (v / v) NP-40, 1mM EDTA, 0.1mM DTT and 0.2mM PMSF). For RNA and DNA digestion, a magnetic bead suspension containing TDP-43 bound to a V5 tag was incubated with DNase, RNase or buffer (control) at 37°C for 10 minutes. After digestion, all reaction mixtures were washed once with ice-cold IPB and resuspended in IVIB. Purified TDP-43 and 14-3-3θ were then incubated for 2 hours at 4°C for in vitro interaction. Reactions were washed as per normal IP and eluted in 4x sample buffer for western blotting.
[0097] Quantitative PCR. RNA purification and quantitative PCR were performed as previously described (Bi et al., 2017, Nat Commun 8: 473). In brief, RNA was extracted from mouse cortical brain tissue using the RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. To remove contaminated genomic DNA, RNase-free DNase I (Qiagen) was used for on-column DNA digestion. cDNA was synthesized from 2.5 μg of total RNA using a second-strand cDNA synthesis kit (Invitrogen). mRNA levels were determined by quantitative PCR using a fast SYBR green reaction mixture (Invitrogen) and gene-specific primer pairs using an Mx3000 real-time PCR cycler (Stratagene). Levels were expressed as fold changes of the housekeeping gene Gapdh and converted to fold differences relative to control tissues. These primers (5' to 3') were used:
[0098] 14-3-3θ
[0099] (F): GCTAAACGGCTTTTGATGAGG (SEQ ID NO: 7);
[0100] (R):GTGCCCTGGATGCCTTTAGTT(SEQ ID NO:8)
[0101] 14-3-3β
[0102] (F): CTCCAGTCCTCCGCGAAAAT (SEQ ID NO: 9);
[0103] (R):GAGAGTTCGTGTCCCTGCTC(SEQ ID NO:10)
[0104] 14-3-3γ
[0105] (F):GGCGGTCTTCGGTTTCCTTC (SEQ ID NO: 11);
[0106] (R):GTTCAGTCGGTCACGTTCTT(SEQ ID NO:12)
[0107] 14-3-3ε
[0108] (F): CGCACCCCATTCGTTTAGG (SEQ ID NO: 13);
[0109] (R):ATTCTGCTCTTCACCATCACC(SEQ ID NO:14)
[0110] 14-3-3ζ
[0111] (F): CTACGATCACGTCCAACCCG (SEQ ID NO: 15);
[0112] (R):GTCAAACGCTTCTGGCTGC(SEQ ID NO:16)
[0113] 14-3-3σ
[0114] (F):ACAACCTGACACTGTGGACG (SEQ ID NO:17);
[0115] (R): CCTTTGGAGCAAGAACAGCG (SEQ ID NO:18)
[0116] Gapdh
[0117] (F):GTGAAGGTCGGTGTGAAC (SEQ ID NO: 19);
[0118] (R):ATCTCCACTTTGCCACTGCAA(SEQ ID NO:20)
[0119] Mouse. iTDP-43 has been described previously A315T Mice (Ke et al., 2015, Acta Neuropathol 130: 661-678). These mice constitutively express human A315T mutant TDP-43 in CNS neurons under the control of a doxycycline-controlled (Tet-OFF) promoter. Mice were group-housed in a 12-hour light / dark cycle with free access to food and water. Time-matched C57Bl / 6 mice were obtained from ARC Perth. All animal experiments have been approved by the Animal Ethics Committee of Macquarie University.
[0120] Motor test - The wire test was performed as previously described (van Hummel et al., 2018, Am J Pathol 188: 1447-1456). Briefly, mice were placed on a wire mesh and hung upside down, and the latency to fall was recorded. Grip strength was obtained by measuring peak forearm strength using a hand dynamometer (Chatillon, AMETEK) as previously described (Am J Pathol 188, 1447-1456).
[0121] Immunohistochemistry. Staining of paraffin tissue sections, including antigen retrieval, has been described previously (van Eersel et al., 2015, Neuropathology and Applied Neurobiology 41:906-925). The primary antibodies used for staining were against human TDP-43, pan-TDP-43 (ProteinTech). NeuN, mCherry, EGFP (Abcam), V5 (Sigma). The secondary antibodies used were Alexa-Fluo conjugated 488, 555, and 647 (Life Technologies).
[0122] Statistical analysis. Statistical analysis was performed using GraphPad Prism 6.0. Student's t-test was used to compare two groups, and ANOVA was used for multiple group comparisons.
[0123] Example 1 - Identification of novel interacting partners of TDP-43
[0124] To identify novel interacting partners of the C-terminal glycine-rich domain (GRD) of TDP-43, the inventors performed a bacterial two-hybrid screen as described above. The best candidates identified (11 of 65 hits) were 14-3-3θ (encoded by the YWHAQ gene), a member of the 14-3-3 scaffold protein family. Co-immunoprecipitations from murine N2a cells and mouse brain confirmed the interaction between endogenous 14-3-3θ and TDP-43 ( Figure 1 ).
[0125] To test whether the 14-3-3θ / TDP-43 interaction is disease-related, the inventors expressed 14-3-3θ and TDP-43 mutants in 293T HEK cells. Surprisingly, 14-3-3θ interacted significantly more with TDP-43 variants carrying pathogenic mutations, including the A315T mutation, which is a pathogenic variant associated with familial ALS and FTD (see Figure 2 ). Co-expression of 14-3-3θ and TDP-43-A315T resulted in significant cytoplasmic colocalization ( Figure 3 A). Nuclear localization (NLS) and nuclear export (NES) sequences mediate the predominant nuclear localization of TDP-43. Interestingly, 14-3-3θ exhibited strong interactions with both the NES deletion (ΔNES) and NLS deletion (ΔNLS) variants of TDP-43 ( Figure 3B). Although the cytoplasmic localization of TDP-43-ΔNLS and the nuclear localization of non-mutant TDP-43 were not altered by 14-3-3θ, TDP-43-ΔNES (Winton et al., 2008, J Biol Chem 283:13302-13309), which is strictly localized to the nucleus and forms nuclear aggregates when expressed in cells, was found to be almost exclusively present in the cytoplasm when co-transfected with 14-3-3θ ( Figure 3 C).
[0126] The above findings demonstrate that the inventors have identified a novel interaction between 14-3-3θ and TDP-43, with enhanced complex formation driving the cytoplasmic localization of TDP-43 variants, including pathogenic variants.
[0127] Then, the inventors tested the potential interaction of all 14-3-3 isoforms with TDP-43 by coimmunoprecipitation. Compared with 14-3-3θ, TDP-43 shows stronger interaction with 14-3-3η, 14-3-3γ and 14-3-3σ isoforms, but no obvious interaction with 14-3-3ε, 14-3-3ζ and 14-3-3β (data not shown). 14-3-3σ and 14-3-3ζ isoforms are not enriched in neurons. More importantly, compared with wild-type TDP-43, only 14-3-3θ shows significantly stronger interaction with TDP-43-A315T, particularly TDP-43-ΔNES variants, while other interacting isoforms do not show enhanced interaction (in fact 14-3-3σ interacts less with TDP-43-ΔNES) (data not shown). Therefore, only the interaction with 14-3-3θ is altered with pathogenic variants of TDP-43.
[0128] Example 2 - Interaction motifs in 14-3-3θ mediating binding to TDP-43
[0129] 14-3-3 dimers usually interact with the phosphorylated forms of their interaction partners. In contrast, however, in the case of TDP-43, the inventors found that phosphorylation mimetic variants of TDP-43 interacted less with 14-3-3θ, supporting a non-canonical type of interaction (data not shown).
[0130] Structurally, 14-3-3θ contains nine α-helices (see Figure 4 ), of which helices αC, αE, αG, and αI contribute to the typical partner binding of the 14-3-3θ dimer. To identify the interaction motif in 14-3-3θ that mediates TDP-43 binding, the inventors gradually truncated 14-3-3θ and revealed that the interaction is mediated by the sixth α-helix (αF) of 14-3-3θ ( Figure 4 ).
[0131] The inventors generated a construct containing only α-helix 6 (αF) of 14-3-3θ (the 30 amino acid sequence shown in SEQ ID NO: 2; corresponding to amino acids 135-164 of the wild-type human TDP-43 sequence), and termed this construct "Fx". Expression of Fx resulted in the coprecipitation of TDP-43 ( Figure 5 ), but failed to pull down the known 14-3-3θ interacting partners YES-associated protein (YAP) and FOXO1 (data not shown), further supporting a non-canonical interaction between 14-3-3θ and TDP-43. α-Helix 6 (αF) of 14-3-3θ has a 10-amino acid motif that is unique to 14-3-3θ compared to other 14-3-3 isoforms ( Figure 6 ), presented on opposite surfaces of the 14-3-3θ dimer and distinct from the conical interaction site in the center of the molecule, explaining the unconventional interaction with TDP-43.
[0132] Example 3 - Effects of increased 14-3-3θ expression in vivo
[0133] To investigate the effects of increased 14-3-3θ levels in vivo, the inventors used adeno-associated virus (AAV) to infect three-month-old non-transgenic mice and iTDP-43 A315T Increasing neuronal 14-3-3θ levels leads to the accumulation of insoluble TDP-43 fragments in non-transgenic mice and to the accumulation of 14-3-3θ in iTDP-43 A315T This is especially true in mice ( Figure 7 A) In addition, AAV-14-3-3θ injected iTDP-43 A315T Mice showed a substantial loss of hippocampal neurons expressing hTDP-43 ( Figure 7 B) Therefore, increased 14-3-3θ levels in vivo lead to disease-like insolubility and fragmentation of endogenous and transgenic TDP-43, further exacerbating iTDP-43 A315T Neuropathological phenotypes of mice.
[0134] The inventors also tested the Whether long-term AAV-mediated 14-3-3θ overexpression in the spinal cord of C57Bl / 6 mice leads to altered endogenous TDP-43 and functional defects. Histopathological analysis of the spinal cord after 10 months of 14-3-3θ overexpression showed cytoplasmic accumulation of TDP-43 in anterior horn motor neurons overexpressing 14-3-3θ, while non-expressing or GFP control cells only presented nuclear TDP-43 (data not shown). Therefore, long-term increased 14-3-3θ levels impair the localization of TDP-43 in motor neurons and lead to functional motor defects.
[0135] Example 4 - 14-3-3θ-Fx Targeted Degradation of Pathological TDP-43
[0136] The unique interaction mode between 14-3-3θ and TDP-43 and the preference of 14-3-3θ for abnormal forms of TDP-43 prompted the inventors to explore whether 14-3-3θ can be used to therapeutically target pathological TDP-43. The inventors designed a construct (referred to herein as 'DD-θFx') comprising 14-3-3θ-Fx (Example 2) fused to a C-terminal degradation domain (DD) from the PTuner plasmid (Clonetech) and an N-terminal V5 tag for detection. DD-θFx was shown to accumulate in primary neurons only in the presence of the stabilizing compound Shield1, confirming efficient DD-induced degradation in neurons ( Figure 8 A). Co-expression of DD-θFx with A315T mutant human TDP-43 (hTDP-43) in neurons resulted in a significant decrease in hTDP-43 levels, consistent with induced degradation ( Figure 8 B) In addition, AAV-mediated DD-θFx expression in iTDP-43 A315T Expression in mouse brain results in mutually exclusive expression of transgenic hTDP-43 and DD-θFx ( Fig. 9 A) and decreased TDP-43 levels ( Fig. 9 B) This indicates clearance of transgenic hTDP-43 mediated by degradation of DD-θFx. The turnover rate of DD-θFx in control mice is higher than that of iTDP-43 A315T mice, which may be due to iTDP-43 A315T Presence of TDP-43 aggregates in mice. iTDP-43 injected with control vector A315T Compared with mice expressing DD-θFx, iTDP-43 A315T Functional assessments of the mice showed less disinhibition, less hyperactivity, reduced motor deficits, and increased muscle strength ( Fig.10 ). Thus, DD-θFx induces targeted degradation of pathogenic TDP-43 in neurons and prevents iTDP-43 A315T Defects in mice.
[0137] The inventors then used the neurotrophic AAV serotype AAV.PHP.B (Deverman et al., 2016, Nat Biotechnol 34:204-209), which allows systemic delivery of DD-θFx (or control) to three-month-old iTDP-43 mice with established defects. A315T Western blot confirmed that iTDP-43 expressing DD-θFx was upregulated compared with controls. A315T Reduction of hTDP-43 in mice ( Fig.11 A). This resulted in comparable and reproducible expression patterns of DD-θFx and control vector throughout the CNS over a two-week period ( Fig.11 B). Importantly, a 32.6 ± 6.6% reduction in hTDP-43-expressing neurons was observed in the absence of overt cell loss. Furthermore, DD-θFx colocalized with hTDP-43 in the remaining neurons, many of which showed only weak transgenic TDP-43 staining. A315T Mice (i.e., 2 weeks after DD-θFx AAV delivery) were functionally assessed. At this age, untreated iTDP-43 A315T Mice showed severe damage (Ke et al., 2015 Acta Neuropathol 130:661-678). Notably, DD-θFx expression improved iTDP-43 A315T Disinhibition in mice Fig.12 ). Expression of the control vector had no significant effect on iTDP-43 in these tasks. A315T The defect in the mice had no effect. DD-θFx left the performance of control mice unaffected. In conclusion, neuronal DD-θFx expression reduced TDP-43 levels and improved iTDP-43 A315T These data suggest that pathological TDP-43 could be targeted and cleared using specific interacting peptides, similar to potential new avenues for treating ALS and FTD.
[0138] Example 5 - DD-θFx prevents defects induced by expression of human wild-type TDP-43 in mice
[0139] Then, the inventors studied the effect of DD-θFx expression in a sporadic ALS mouse model based on the expression of AAV-mediated non-mutated hTDP-43 in CNS neurons. The inventors used the neurotropic AAV9 serotype AAV.PHP.B to achieve systemic delivery and uniform expression in CNS neurons by temporal vein injection in naive newborn C57Bl / 6 mice (Deverman et al., 2016, Nat Biotechnol 34: 204-209). The effect of DD-θFx was studied by co-injection (AAV-DD-θFx) at birth in mice injected with natural hTDP-43 (AAV-hTDP-43) or a single AAV vector (AAV-ctr).
[0140] Until 10 weeks of age, AAV-hTDP-43 and AAV-ctr showed comparable performance in biweekly inverted silk tests ( Fig.13 ), indicating comparable strength. Thereafter, performance in the inverted silk test gradually declined in mice administered AAV-hTDP-43, but this was completely prevented when mice were co-treated with AAV-DD-θFx at birth ( Fig.13 Direct assessment of grip strength confirmed this result, with grip strength significantly reduced in male AAV-hTDP-43 mice compared with AAV-ctr mice and prevented by DD-θFx co-treatment ( Fig.14 A comparable trend was observed in female mice. In addition, tibialis anterior muscle weights were significantly reduced in both female and male AAV-hTDP-43 mice at 19 weeks of age compared to their respective controls ( Fig.15 ). These results indicate that DD-θFx prevents the defects caused by expression of non-mutant TDP-43 in mice. Sequence Listing <110> Macquarie University <120> Compositions and methods for treatment <130> 35527800 <160> 20 <170> PatentIn version 3.5 <210> 1 <211> 11 <212> PRT <213> Homo sapiens <400> 1 Arg Lys Gln Thr Ile Asp Asn Ser Gln Gly Ala 1 5 10 <210> 2 <211> 30 <212> PRT <213> Homo sapiens <400> 2 Gly Asp Asp Arg Lys Gln Thr Ile Asp Asn Ser Gln Gly Ala Tyr Gln 1 5 10 15 Glu Ala Phe Asp Ile Ser Lys Lys Glu Met Gln Pro Thr His 20 25 30 <210> 3 <211> 245 <212> PRT <213> Homo sapiens <400> 3 Met Glu Lys Thr Glu Leu Ile Gln Lys Ala Lys Leu Ala Glu Gln Ala 1 5 10 15 Glu Arg Tyr Asp Asp Met Ala Thr Cys Met Lys Ala Val Thr Glu Gln 20 25 30 Gly Ala Glu Leu Ser Asn Glu Glu Arg Asn Leu Leu Ser Val Ala Tyr 35 40 45 Lys Asn Val Val Gly Gly Arg Arg Ser Ala Trp Arg Val Ile Ser Ser 50 55 60 Ile Glu Gln Lys Thr Asp Thr Ser Asp Lys Lys Leu Gln Leu Ile Lys 65 70 75 80 Asp Tyr Arg Glu Lys Val Glu Ser Glu Leu Arg Ser Ile Cys Thr Thr 85 90 95 Val Leu Glu Leu Leu Asp Lys Tyr Leu Ile Ala Asn Ala Thr Asn Pro 100 105 110 Glu Ser Lys Val Phe Tyr Leu Lys Met Lys Gly Asp Tyr Phe Arg Tyr 115 120 125 Leu Ala Glu Val Ala Cys Gly Asp Asp Arg Lys Gln Thr Ile Asp Asn 130 135 140 Ser Gln Gly Ala Tyr Gln Glu Ala Phe Asp Ile Ser Lys Lys Glu Met 145 150 155 160 Gln Pro Thr His Pro Ile Arg Leu Gly Leu Ala Leu Asn Phe Ser Val 165 170 175 Phe Tyr Tyr Glu Ile Leu Asn Asn Pro Glu Leu Ala Cys Thr Leu Ala 180 185 190 Lys Thr Ala Phe Asp Glu Ala Ile Ala Glu Leu Asp Thr Leu Asn Glu 195 200 205 Asp Ser Tyr Lys Asp Ser Thr Leu Ile Met Gln Leu Leu Arg Asp Asn 210 215 220 Leu Thr Leu Trp Thr Ser Asp Ser Ala Gly Glu Glu Cys Asp Ala Ala 225 230 235 240 Glu Gly Ala Glu Asn 245 <210> 4 <211> 33 <212> DNA <213> Homo sapiens <400> 4 cgaaaacaaa cgatagataa ttcccaagga gct 33 <210> 5 <211> 90 <212> DNA <213> Homo sapiens <400> 5 ggtgatgatc gaaaacaaac gatagataat tcccaaggag cttaccaaga ggcatttgat 60 ataagcaaga aagagatgca acccacaacac 90 <210> 6 <211> 58 <212> DNA <213> Artificial sequence <220> <223> synthetic sequence <400> 6 ccggcagttg cttagagaca acctactcga gtaggttgtc tctaagcaac tgtttttg 58 <210> 7 <211> twenty two <212> DNA <213> Artificial sequence <220> <223> synthetic sequence <400> 7 gctaaaacgg cttttgatga gg 22 <210> 8 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> synthetic sequence <400> 8 gtgccctgga tgcctttagt t 21 <210> 9 <211> 20 <212> DNA <213> Artificial sequence <220> <223> synthetic sequence <400> 9 ctccagtcct ccgcgaaaat 20 <210> 10 <211> 20 <212> DNA <213> Artificial sequence <220> <223> synthetic sequence <400> 10 gagagttcgt gtccctgctc 20 <210> 11 <211> 20 <212> DNA <213> Artificial sequence <220> <223> synthetic sequence <400> 11 ggcggtcttc ggtttccttc 20 <210> 12 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> synthetic sequence <400> 12 gttcagctcg gtcacgttct t 21 <210> 13 <211> 19 <212> DNA <213> Artificial sequence <220> <223> synthetic sequence <400> 13 cgcaccccat tcgtttagg 19 <210> 14 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> synthetic sequence <400> 14 attctgctct tcaccatcac c 21 <210> 15 <211> 20 <212> DNA <213> Artificial sequence <220> <223> synthetic sequence <400> 15 ctacgatcac gtccaacccg 20 <210> 16 <211> 19 <212> DNA <213> Artificial sequence <220> <223> synthetic sequence <400> 16 gtcaaacgct tctggctgc 19 <210> 17 <211> 20 <212> DNA <213> Artificial sequence <220> <223> synthetic sequence <400> 17 acaacctgac actgtggacg 20 <210> 18 <211> 20 <212> DNA <213> Artificial sequence <220> <223> synthetic sequence <400> 18 cctttggagc aagaacagcg 20 <210> 19 <211> 18 <212> DNA <213> Artificial sequence <220> <223> synthetic sequence <400> 19 gtgaaggtcg gtgtgaac 18 <210> 20 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> synthetic sequence <400> 20 atctccactt tgccactgca a 21
Claims
1. Use of a peptide consisting of the amino acid sequence of SEQ ID NO: 2, or a nucleic acid molecule encoding the peptide, in the manufacture of a medicament, wherein the medicament is used to treat, prevent or improve a neurodegenerative disease associated with TDP-43 pathology.
2. The method according to claim 1, wherein the neurodegenerative disease is selected from amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
3. The use according to claim 1, comprising administering a nucleic acid molecule encoding the peptide sequence, wherein the peptide sequence consists of the amino acid sequence of SEQ ID NO:
2. 4 . The use according to claim 3 , wherein the nucleic acid molecule encoding the peptide of SEQ ID NO: 2 comprises the nucleotide sequence of SEQ ID NO:
5.
5. The use according to claim 1, wherein the peptide is linked to a protein destabilizing domain sequence. The use according to claim 5, wherein the protein destabilizing domain sequence comprises rapamycin binding protein FKBP12.
7. The use according to claim 1, wherein the use comprises administering to a subject a gene construct encoding a peptide consisting of the amino acid sequence of SEQ ID NO: 2, wherein the gene construct is operably linked to a nucleotide sequence encoding a protein destabilizing domain.
8. An isolated peptide consisting of the amino acid sequence of SEQ ID NO:
2.
9. The peptide according to claim 8, for use in treating or preventing or ameliorating neurodegenerative diseases associated with TDP-43 pathology.
10. An isolated polynucleotide encoding the peptide of claim 8.
11. A chimeric molecule comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 2 linked to a protein destabilizing domain sequence.
12. An isolated polynucleotide encoding the chimeric molecule of claim 11. A vector comprising the polynucleotide according to claim 12.
14. The vector of claim 13, wherein the vector is an AAV vector.
15. Use of the chimeric molecule according to claim 11 or the vector according to claim 13 in the manufacture of a medicament, wherein the medicament is used to treat, prevent or ameliorate a neurodegenerative disease associated with TDP-43 pathology.
